InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights NV-387 as Potential Treatment for Growing Measles Outbreaks
NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing broad-spectrum antivirals using host-mimetic nanomedicine technology, announced its drug candidate NV-387 could address rising measles cases in the United States, Canada, the UK and European Union. NV-387 has shown effectiveness and safety in animal studies using humanized h-CD150+ knock-in mice and completed a Phase I clinical trial with no adverse events, indicating strong tolerability in humans.…